Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for GRRMF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for GRRMF and 80,000+ other tickers.
See exactly how GRRMF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for GRRMF and 80,000+ other tickers.
Gerresheimer AG, alongside its global subsidiaries, stands as a prominent manufacturer of packaging solutions and drug delivery devices. The company's operations are segmented into three primary divisions. The Plastics & Devices division supplies a comprehensive range of drug delivery systems, including inhalers, insulin pen systems, prefillable syringes, and diagnostic tools, serving the pharmaceutical, biotechnology, diagnostics, and medical technology sectors. This segment also produces various plastic containers and closures, such as PET bottles, eye droppers, nasal sprays, nebulizers…
German drugs packaging firm Gerresheimer said on Wednesday it was selling two of its packaging units to private equity group Apax Funds for €1.5 billion ($1.71 billion) including debt.
Gerresheimer ETR: GXI said it has completed a broad review of compliance and accounting matters, published its audited 2025 annual report and is now focused on selling Centor, refinancing debt and improving cash generation.
German medical packaging maker Gerresheimer has rejected a takeover bid from its U.S. rival Silgan , three sources familiar with the situation told Reuters.
Gerresheimer on Tuesday again deferred the release of 2025 financial statements to June, citing a probe into its business deals, a delay that is now set to cost the German medical products maker its place on the Deutsche Boerse's SDAX index.
Diamond Hill International Strategy returned 3.87% (net of fees) and the MSCI ACWI ex USA Index returned 5.05%. Sumitomo Densetsu, a Japanese electrical contractor, benefited from a takeover bid by Daiwa House, whose tender offer at a premium price drove the stock higher. Stock selection in information technology and industrials contributed, along with our overweight to communication services.